相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Does ruxolitinib prolong the survival of patients with myelofibrosis?
Francisco Cervantes et al.
BLOOD (2017)
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
A. Tefferi et al.
LEUKEMIA (2017)
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis
Juan-Carlos Hernandez-Boluda et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
Malte Asshoff et al.
BLOOD (2017)
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Maximilian Stahl et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Haifa Kathrin Al-Ali et al.
HAEMATOLOGICA (2016)
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
C. N. Harrison et al.
LEUKEMIA (2016)
Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
Claire N. Harrison et al.
LEUKEMIA & LYMPHOMA (2016)
Ruxolitinib therapy and telomere length in myelofibrosis
G. Caocci et al.
BLOOD CANCER JOURNAL (2016)
Epigenetics in Cancer: A Hematological Perspective
Maximilian Stahl et al.
PLOS GENETICS (2016)
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Haifa Kathrin Al-Ali et al.
HAEMATOLOGICA (2016)
Dengue virus binding and replication by platelets
Ayo Y. Simon et al.
BLOOD (2015)
Early bone marrow involvement by mantle cell lymphoma
Parker W. Clement et al.
BLOOD (2015)
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
Adam J. Mead et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
Sara C. Meyer et al.
CANCER CELL (2015)
Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities
Koen Schepers et al.
CELL STEM CELL (2015)
A comprehensive review of pacritinib in myelofibrosis
Srdan Verstovsek et al.
FUTURE ONCOLOGY (2015)
Higher levels of reactive oxygen species are associated with anergy in chronic lymphocytic leukemia
Adam Linley et al.
HAEMATOLOGICA (2015)
DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
Jyoti Nangalia et al.
HAEMATOLOGICA (2015)
JAK Inhibitors and myelofibrosis, Einstein and ruxolitinib
Claire Harrison
HAEMATOLOGICA (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2015)
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Naval Daver et al.
HAEMATOLOGICA (2015)
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Treating Myeloproliferation - On Target or Off?
Mary Armanios et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
S. Cerquozzi et al.
BLOOD CANCER JOURNAL (2015)
Higher levels of reactive oxygen species are associated with anergy in chronic lymphocytic leukemia
Adam Linley et al.
HAEMATOLOGICA (2015)
DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
Jyoti Nangalia et al.
HAEMATOLOGICA (2015)
JAK Inhibitors and myelofibrosis, Einstein and ruxolitinib
Claire Harrison
HAEMATOLOGICA (2015)
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Naval Daver et al.
HAEMATOLOGICA (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2015)
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer
A. A. Chiappori et al.
ANNALS OF ONCOLOGY (2015)
SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation
S. Bartels et al.
LEUKEMIA (2015)
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Elisa Rumi et al.
BLOOD (2014)
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms
Neha Bhagwat et al.
BLOOD (2014)
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
Raajit Rampal et al.
BLOOD (2014)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg et al.
BLOOD (2014)
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms
Mario Cazzola et al.
BLOOD (2014)
Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
Raoul Tibes et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype
A. Tefferi et al.
LEUKEMIA (2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A. Tefferi et al.
LEUKEMIA (2014)
Novel myelofibrosis treatment strategies: potential partners for combination therapies
B. L. Stein et al.
LEUKEMIA (2014)
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
P. Guglielmelli et al.
LEUKEMIA (2014)
Definition and management of ruxolitinib treatment failure in myelofibrosis
A. Pardanani et al.
BLOOD CANCER JOURNAL (2014)
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
SRSF2 mutation is present in the hypercellular and prefibrotic stage of primary myelofibrosis
Ulrich Lehmann et al.
BLOOD (2013)
Efficacy and safety of pegylated-interferon-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups
Jean-Christophe Ianotto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis
Daniel J. DeAngelo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
John Mascarenhas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Rationale for Targeting the PI3K/Akt/mTOR Pathway in Myeloproliferative Neoplasms
Niccolò Bartalucci et al.
Clinical Lymphoma Myeloma & Leukemia (2013)
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2013)
Genetic and epigenetic alterations of myeloproliferative disorders
Jelena D. Milosevic et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A. Pardanani et al.
LEUKEMIA (2013)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
Chromosome 5q deletion is extremely rare in patients with myelofibrosis
Koichi Takahashi et al.
LEUKEMIA RESEARCH (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Comprehensive review of JAK inhibitors in myeloproliferative neoplasms
Mohamad Bassam Sonbol et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
Muhammad Furqan et al.
BIOMARKER RESEARCH (2013)
Apoptosis deregulation in myeloproliferative neoplasms
Raquel Tognon et al.
EINSTEIN-SAO PAULO (2013)
Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection
Nikolaos Papadantonakis et al.
BLOOD (2012)
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation
Bart L. Scott et al.
BLOOD (2012)
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
Terra L. Lasho et al.
BLOOD (2012)
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
Hideki Makishima et al.
BLOOD (2012)
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis
Albert Deisseroth et al.
CLINICAL CANCER RESEARCH (2012)
CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2
Paula Aranaz et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
Raquel Tognon et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
A. Tefferi et al.
LEUKEMIA (2012)
SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients
T. L. Lasho et al.
LEUKEMIA (2012)
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Priya Koppikar et al.
NATURE (2012)
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
Lambert Busque et al.
NATURE GENETICS (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
How to manage the transplant question in myelofibrosis
K. Ballen
BLOOD CANCER JOURNAL (2012)
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli et al.
BLOOD (2011)
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression
Thorsten Klampfl et al.
BLOOD (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
DNMT3A mutations in myeloproliferative neoplasms
F. Stegelmann et al.
LEUKEMIA (2011)
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida et al.
NATURE (2011)
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2011)
p53 Lesions in Leukemic Transformation
Ashot Harutyunyan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
Alejandra Martinez-Trillos et al.
ANNALS OF HEMATOLOGY (2010)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
Ruben A. Mesa et al.
BLOOD (2010)
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
Sylvain Thepot et al.
BLOOD (2010)
Cbl and Human Myeloid Neoplasms: The Cbl Oncogene Comes of Age
Stephen C. Kales et al.
CANCER RESEARCH (2010)
Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis
Sameer A. Parikh et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
Sachie Marubayashi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Targeting leukemic stem cells by breaking their dormancy
Marieke Alida Gertruda Essers et al.
MOLECULAR ONCOLOGY (2010)
Targeting leukemia stem cells
Hanna K. A. Mikkola et al.
NATURE BIOTECHNOLOGY (2010)
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst et al.
NATURE GENETICS (2010)
Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms
Anthony Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
Francis H. Grand et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Mutations of ASXL1 gene in myeloproliferative neoplasms
N. Carbuccia et al.
LEUKEMIA (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
Masashi Sanada et al.
NATURE (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Does primary myelofibrosis involve a defective stem cell niche?: From concept to evidence
Jean-Jacques Lataillade et al.
BLOOD (2008)
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
A. Quintas-Cardama et al.
LEUKEMIA (2008)
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
Daniela Pietra et al.
BLOOD (2008)
Lenalidomide therapy in del(5)(q31)-associated myelofibrosis:: cytogenetic and JAK2V617F molecular remissions
A. Tefferi et al.
LEUKEMIA (2007)
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis
Stefan O. Ciurea et al.
BLOOD (2007)
The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: Retrospective analysis of 39 patients in japan
Kazuya Shimoda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis
S. N. Tsiara et al.
ACTA HAEMATOLOGICA (2007)
JAK-2 mutations and their relevance to myeloproliferative disease
Ross L. Levine et al.
CURRENT OPINION IN HEMATOLOGY (2007)
The JAK-STAT pathway: A therapeutic target in hematological malignancies
A. Ferrajoli et al.
CURRENT CANCER DRUG TARGETS (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia
Francisco Cervantes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
JAW/STAT signal transduction: Regulators and implication in hematological malignancies
L Valentino et al.
BIOCHEMICAL PHARMACOLOGY (2006)
c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses
CBF Thien et al.
BIOCHEMICAL JOURNAL (2005)
Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia:: long-term results in 30 patients
F Cervantes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases
RA Mesa et al.
BLOOD (2005)
分享论文
